Cephalon drops collaboration with Alkermes for Vivitrol
Alkermes said its partnership with Cephalon on Vivitrol, an injectable treatment for alcoholism, was discontinued. The decision, which is a result of Cephalon's portfolio evaluation, comes months after U.S. health authorities said they got 196 reported cases of complications from people who took Vivitrol.
Reuters | 12/01
This story published in BIO SmartBrief on 12/02/2008
More from SmartBrief:
Xoma to get $6M from Cephalon unit for antibody R&D
Thursday, September 10, 2009
Cephalon completes acquisition of Arana for $207 million
Tuesday, August 11, 2009
Cephalon secures option to acquire biopharmaceutical firm
Tuesday, October 27, 2009
Get stories like these delivered daily for FREE:
|
BIO SmartBrief
Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more |
|